CIK cells + folinic acid + fluorouracil + oxaliplatin

This is a combination therapy consisting of cytokine-induced killer (CIK) cells, folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. - **CIK cells** are ex vivo expanded immune effector cells with both T cell and natural killer cell properties. They exert antitumor effects through MHC-unrestricted cytotoxicity mediated by NK cell receptors such as NKG2D, DNAM-1, NKp30, and others. CIKs kill tumor cells via perforin/granzyme release and FasL-mediated apoptosis while secreting pro-inflammatory cytokines like IFN-γ and TNF-α to enhance systemic antitumor immunity[6][8][9]. - **Folinic acid** is a reduced form of folic acid that enhances the binding of 5-fluorouracil to thymidylate synthase, increasing its cytotoxic effect[3]. - **Fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis in rapidly dividing cancer cells[3]. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks leading to apoptosis in cancerous tissues[3]. The combination of these agents leverages direct cytotoxicity from chemotherapy (folinic acid/fluorouracil/oxaliplatin—commonly known as FOLFOX) with the immunotherapeutic activity of adoptively transferred CIK cells. This approach aims for synergistic effects against solid tumors such as colorectal cancer by combining immune-mediated tumor killing with standard chemotherapy regimens[6][9].

Other names

FOLFOX plus CIK cellsFOLFOX combined with cytokine-induced killer cells